Deutsches Herzzentrum München, Technische Universität, Munich, Germany.
Institut für Laboratoriumsmedizin, Deutsches Herzzentrum München, Technische Universität, Munich, Germany.
Eur J Clin Invest. 2021 Jul;51(7):e13514. doi: 10.1111/eci.13514. Epub 2021 Feb 24.
The association between elevated creatine kinase (CK) and bleeding in patients with acute coronary syndrome (ACS) remains incompletely investigated. We undertook this study to assess whether there is an association between elevated CK activity and the risk for bleeding in contemporary patients with ACS.
This post hoc analysis of a randomized trial included 3368 patients with ACS undergoing percutaneous coronary intervention. CK was measured serially in all patients until hospital discharge. The main outcome was 30-day incidence of major bleeding (type 3 to 5 bleeding according to the Bleeding Academic Research Consortium criteria).
Patients were categorized in groups according to the peak CK tertiles: 1st tertile (CK ≤259 U/L; n = 1127 patients), 2nd tertile (CK ≥260 to 990 U/L; n = 1119 patients), and 3rd tertile (CK ≥ 991 U/L; n = 1122 patients). Peak CK activity was higher in patients with bleeding than those without bleeding (771 [316-1845] U/L vs. 496 [190-1357] U/L; P <.001). Bleeding occurred in 26 patients (2.3%) with peak CK within 1st tertile, 39 patients (3.5%) with peak CK within 2nd tertile, and 54 patients (4.8%) with peak CK within 3rd tertile (univariable hazard ratio [HR]=1.39, 95% confidence interval [CI] 1.08 to 1.81, P =.012, per tertile increment in CK values). After adjustment, peak CK activity remained significantly associated with the 30-day bleeding (HR = 1.67 [1.16-2.41]; P =.006 per unit increment in logarithmic CK values). The C statistic of the multivariable model with CK activity was 0.807 [0.770-0.842].
In patients with ACS, peak CK activity was independently associated with increased 30-day incidence of bleeding.
肌酸激酶(CK)升高与急性冠状动脉综合征(ACS)患者出血之间的关联尚未完全明确。我们开展此项研究旨在评估 ACS 患者 CK 活性升高与出血风险之间是否存在关联。
本研究为一项随机试验的事后分析,共纳入 3368 例行经皮冠状动脉介入治疗的 ACS 患者。所有患者均连续检测 CK,直至出院。主要终点为 30 天内主要出血(根据 Bleeding Academic Research Consortium 标准,3 至 5 级出血)的发生率。
根据 CK 峰值的三分位值将患者分组:第 1 组(CK≤259 U/L,n=1127 例)、第 2 组(CK≥260 至 990 U/L,n=1119 例)和第 3 组(CK≥991 U/L,n=1122 例)。出血患者的 CK 峰值高于无出血患者(771[316-1845]U/L 比 496[190-1357]U/L;P<0.001)。第 1 组、第 2 组和第 3 组 CK 峰值范围内分别有 26 例(2.3%)、39 例(3.5%)和 54 例(4.8%)患者发生出血(单变量风险比[HR]=1.39,95%置信区间[CI]1.08 至 1.81,P=0.012,CK 值每增加一个三分位)。校正后,CK 活性仍与 30 天出血显著相关(HR=1.67[1.16-2.41];每单位 CK 值对数增加时 P=0.006)。包含 CK 活性的多变量模型的 C 统计量为 0.807[0.770-0.842]。
ACS 患者 CK 峰值与 30 天出血发生率增加独立相关。